Search Results

Pharm Country

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process

Athenex, Inc. announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division, Orascovery, and Cell Therapy.

May 14, 2023

·

5 min read

Pictured: Bankruptcy paperwork on desk/JJ Gouin/iS

Business

Athenex Files for Bankruptcy, Cuts 123 Jobs Across New York

Athenex announced it will lay off 79 employees in Buffalo and 44 employees in Clarence as a result of the Chapter 11 filing.

May 17, 2023

·

2 min read

·

Rosemary Scott

Pharm Country

Athenex Announces a Reverse Stock Split - February 14, 2023

Athenex, Inc. announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023.

February 14, 2023

·

4 min read

Policy

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for metastatic breast cancer based solely on CMC issues.

January 3, 2023

·

4 min read

Pharm Country

Athenex Announces Positive Results of Special Stockholder Meeting

Athenex, Inc. announced the results of its special meeting of stockholders, held as a virtual meeting on November 22, 2022.

November 22, 2022

·

1 min read

Business

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2022.

March 20, 2023

·

15 min read

Business

Athenex Provides Third Quarter 2022 Financial Results and Business Update

Athenex, Inc. provided a corporate and financial update for the third quarter ended September 30, 2022.

November 3, 2022

·

14 min read

Pharm Country

Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Athenex announced that management will participate in the 5th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022.

November 8, 2022

·

1 min read

Pharm Country

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. announced that a Nasdaq Hearings Panel has granted the company’s request for continued listing on The Nasdaq Stock Market, subject to the Company’s satisfaction of the minimum $1.00 bid price requirement by March 14, 2023.

November 3, 2022

·

1 min read

Pharm Country

Athenex Files Definitive Proxy Statement for Special Stockholder Meeting

Athenex, Inc. announced that it has filed a definitive proxy statement with the Securities and Exchange Commission in connection with a special meeting of stockholders scheduled on November 22, 2022.

October 11, 2022

·

6 min read